Germany's Merck suffers setback with cancer drug

BERLIN (AP) — German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.

The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.

Merck shares fell 3.1 percent to €98.20 ($129.41) after the announcement early Wednesday.

The company is a separate entity from Merck & Co., which is based in the U.S.

Associated Press
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

You must be logged in to post comments.

Password (case sensitive):
Remember Me:


6450 Papermill Drive Knoxville, TN 37919 Phone - (865) 450-8888; Fax - (865) 450-8869
Copyright © 2015 WVLT-TV Inc. - Designed by Gray Digital Media - Powered by Clickability 184242591 -
Gray Television, Inc.